StageBio Expands Its Global Presence with Acquisition of TPL Path Labs

StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research, announced today its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.

UnitedHealthcare Reimbursement Cuts Have Pathology Groups on Edge

UnitedHealthcare has issued new fee schedules to a number of Texas pathology groups in recent months, raising concerns that a broader effort to lower payment rates could be coming. The UHC action follows moves over the past year and a half by insurer Anthem to significantly cut payment rates for many pathology practices across the country and fits within a broader and long-term trend of public and private payors putting downward pressure on lab reimbursement. Joe Saad, chairman of pathology at Dallas-based Methodist Health System said that his practice received a letter this week from UHC laying out its new rates. He did not provide the new pricing but said that the insurer was “proposing a fee schedule that is very significantly different from the one that we had, and obviously much lower.”

Precipio Completes Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division

Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has completed the non-cash transaction of the transition of Oncometrix’s customer base, as discussed in Precipio’s recent announcement. As stated previously, the transaction with Poplar involves no exchange of cash or equity in consideration, providing non-dilutive impact to shareholders. “We are delighted to complete this transaction and partner with Precipio for the hematopathology business, enabling us to focus on our other core businesses”, said James Sweeney, CEO of Poplar Healthcare. “We look forward to continued collaboration with Precipio in other areas of our partnership”.

Synergy Laboratories Acquires Pathology Laboratory Associates to Broaden Its Medical Testing Expertise

Synergy Laboratories (Synergy) announced today that it has acquired Mobile, Alabama-based Pathology Laboratory Associates (PLA) for an undisclosed price. The combination of PLA’s expertise in pathology and Synergy’s recognized leadership in the field of medical testing will enhance the care delivered to patients throughout the Southeast. PLA’s Vice-President, Dr. Kimberley V. Patterson, sees the combined organizations growing into a regional provider with an emphasis on women’s health. She explained, “We are excited about the opportunities to expand our capability to serve physicians and their patients with comprehensive out-patient laboratory and pathology services. We are especially interested in expanding our services related to women’s health to provide an Alabama-based source for quality, affordable laboratory services.”

StageBio and AlizŽe Pathology Merge

StageBio has merged with AlizŽe Pathology to form the leading provider of specialized histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the mergers of Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists (TPS), and now includes AlizŽe Pathology. StageBio is a portfolio company of Ampersand Capital Partners. “Dr. Serge Rousselle, Dr. Joan Wicks and the AlizŽe staff bring unique histopathology capabilities to StageBio. These services enable us to offer the industry an even broader range of highly specialized histopathology and imaging services,” said Mr. Thomas Galati, StageBio CEO. “We have successfully merged HSRL, VPS and TPS, and are excited to add AlizŽe’s expertise to our growing list of offerings.”

PathGroup Combines Forces with Southeastern Pathology Associates, Growing Pathology Services and Hospital Relationships

PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, announced today that Southeastern Pathology Associates has joined the PathGroup family of pathology practices and laboratories. The strategic combination adds to both organizations’ presence in the Southeast region, particularly in Georgia, where SEPA is headquartered, Florida and South Carolina. PathGroup previously acquired Pathologists Bio-Medical Laboratories (PBM) in 2019, a leading provider of pathology services in North Texas. Together, Nashville-based PathGroup and SEPA will include more than 175 pathologists representing every sub-specialty. This comprehensive pathology network will serve over 95 hospitals and thousands of physician practices across the United States, delivering quality diagnostic results and superior service levels. PathGroup is owned by Pritzker Private Capital along with management.

PHC Holdings Completes Acquisition of Anatomical Pathology Business from Thermo Fisher Scientific

PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) announced Friday the completion of its acquisition of Anatomical Pathology business of Thermo Fisher Scientific Inc. (NYSE: TMO, hereafter Thermo Fisher) for approximately US$1.14 billion. The acquired Anatomical Pathology business will operate as a new stand-alone company named Epredia that will continue to serve as a leading global provider of comprehensive solutions in the anatomical pathology field, including microscope slides, instruments and consumables. PHCHD is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT. Through the acquisition of the Epredia business from Thermo Fisher, PHCHD will strengthen its diagnostics business by expanding its portfolio into oncology to support further business growth.

PathGroup Acquires Pathologists Bio-Medical Laboratories, Expanding Pathology Services and Clinical Innovation

PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, announced Wednesday that it has acquired Pathologists Bio-Medical Laboratories (PBM), a leading provider of pathology services based in Dallas. The combination of Nashville-based PathGroup and PBM will lead to enhanced services and a broader menu of testing across their client base. The combined company will include more than 120 pathologists, representing every sub-specialty, creating one of the most comprehensive pathology networks in the country. It will be comprised of more than 1,800 employees working with more than 75 hospitals and thousands of physicians across the U.S. to deliver quality lab testing and diagnostic results with unmatched responsiveness. Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology services in the United States. PathGroup is owned by Pritzker Private Capital along with management.

EMV Capital Invests in Leading San Francisco-Based Liquid Biopsy Company Vortex Biosciences Inc

EMV Capital announced Thursday the acquisition of a controlling stake in Bay Area-based Vortex Biosciences, and a further investment package to accelerate the company’s development. Vortex Biosciences provides an automated, label-free, benchtop solution for isolation and purification of Circulating Tumor Cells (CTCs) from a standard 8ml tube of blood. The VTX-1 instrument rapidly processes the sample through micro vortices to enrich the CTCs and delivers these highly purified cells into a choice of collection formats. These samples are easily integrated into downstream genomics, protein markers testing, single cell analysis and staining techniques. The blood tube can be processed to also preserve the ctDNA content of the sample for downstream NGS analysis.

PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific

PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) announced Monday that it has signed a definitive agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) (hereafter Thermo Fisher), the world leader in serving science, to acquire Thermo Fisher’s Anatomical Pathology business for approximately US$ 1.14 billion. Thermo Fisher’s Anatomical Pathology business is one of the leading providers of microscope slides, instruments and consumables in the industry and is part of Thermo Fisher’s Specialty Diagnostics Segment, operating in the US, Europe and China with approximately 1,200 employees. PHCHD is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT. Aiming to achieve further business growth, PHCHD will expand its business portfolio through the acquisition of the business from Thermo Fisher.